BioCentury | Dec 8, 2014
Clinical News

CSI Glucagon regulatory update

FDA and the European Commission granted Orphan Drug designation to CSI Glucagon from Xeris to prevent severe, persistent hypoglycemia related to congenital hyperinsulinism. Xeris plans to submit an IND to FDA by year end to...
Items per page:
1 - 1 of 1